Oncology Consultants Join Agendia’s FLEX Big DataRegistry Study, Helping to Build a Unique Resource for Breast Cancer Research

All Oncology Consultants practices participate in the initiative, matching full genome profiles with complete clinical data to create a comprehensive patient database

IRVINE, CALIF., U.S., HOUSTON, TEXAS, U.S., AMSTERDAM, NETHERLANDS 4 December 2018 – Agendia, Inc., a world leader in precision oncology, announced today that Texas-based Oncology Consultants, P.A., a community-based practice of physicians committed to providing state-of-the-art cancer treatment, has joined Agendia’s FLEX breast cancer registry study.

Treating over 800 breast cancer patients each year, all Oncology Consultants practices are now enrolling patients on FLEX, a large-scale, prospective, observational breast cancer study that links full genome profiling, including Agendia’s MammaPrint® Breast Cancer Risk of Recurrence and BluePrint® Molecular Subtyping tests, with complete clinical data. This database, which aims to capture full genomic and clinical data from over 10,000 patients, will provide valuable opportunities to accelerate breast cancer research by enabling researchers to investigate differences and trends in treatment responses between subgroups of patients.

FLEX is open to both women and men in the U.S. diagnosed with stage I, II, or III cancer, including all molecular subtypes. Collating genomic and clinical data from all ethnicities, ages, genders, and from patients with co-morbidities enables valuable research into small, more diverse, patient populations which have traditionally been challenging to recruit in sufficient numbers for clinical trials.

Dr. Julio A. Peguero, Director of Research at Oncology Consultants, P.A., said:

“FLEX is a hugely valuable resource that presents opportunities to further drive breast cancer research and treatment. We are very pleased to offer patients at all of our practices the chance to help other women and men with breast cancer to benefit from new discoveries, simply by allowing their genomic and clinical data to be added to the registry.”

Dr. Luis T. Campos, President of Oncology Consultants, P.A., said:

“FLEX is a unique study that will capture comprehensive information from a complete range of patients with breast cancer, including people of all ages, ethnicities and those with pre-existing conditions. Big Data initiatives like FLEX are key to identifying new prognostic and/or predictive gene associations that may otherwise go unnoticed. At Oncology Consultants, P.A., we are committed to doing everything we can to help advance our understanding of breast cancer and are proud to be the largest practice in Houston enrolling for this study.”

Dr. William Audeh, Chief Medical Officer at Agendia, said:

“It has been greatly encouraging to see the positive response to the FLEX study from the physicians and their patients. Since enrollment began in 2017, we now have over 65 participating centers. Every new center and every new patient who joins this study is helping to build a resource that will have a significant impact on breast cancer research and, we believe, the future of breast cancer management. It is exciting to consider the knowledge that may be gained from a comprehensive library of gene expression data in breast cancer that analyzes over 20,000 genes, correlated with therapeutic interventions and long-term follow-up for over 10,000 patients.”

Agendia’s MammaPrint test analyzes 70 genes most associated with breast cancer recurrence to provide a clear, binary Low or High Risk of cancer recurrence result, while BluePrint analyzes 80 genes, which classify a patient’s breast cancer into functional molecular subtypes. Participants in FLEX will receive MammaPrint, with or without BluePrint testing. Full genome and comprehensive clinical data will be collected and added to the study database.

Click here to find out more about the FLEX study and how to participate.

– Ends –

About MammaPrint

MammaPrint is an in vitro diagnostic medical device, performed as a testing service in a central laboratory, using the 70-gene expression profile of breast cancer tissue samples to assess a patient’s risk for distant metastasis. The device is FDA-cleared and CE-marked, enabling use in the European Union. MammaPrint is indicated for use by physicians as a prognostic marker only, along with other clinical-pathological factors. It is not intended to determine the outcome of disease, nor to suggest or infer an individual patient’s response to therapy.

About BluePrint

BluePrint is an 80-gene complementary laboratory-developed test provided with MammaPrint which allows functional molecular subtyping of a breast cancer sample into three distinct subtypes: Luminal-type, HER2-type and Basal-type, each with marked differences in long-term outcome and response to neoadjuvant chemotherapy.

About Agendia

Agendia is a privately held, leading precision oncology company that develops and markets genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. The company’s offerings include the MammaPrint Breast Cancer Risk-of-Recurrence Test, and the BluePrint Molecular Subtyping Test, both on microarray technology, whereas the new MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit is on NGS technology.

The MammaPrint BluePrint next-generation sequencing-based kit is a CE-marked device currently available for use in cancer centers in select regions of the world.

In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers, and academic groups to develop companion diagnostic tests in the area of oncology. For more information on Agendia or the MammaPrint and BluePrint tests, visit Follow Agendia, Inc. on Facebook, Twitter, or LinkedIn to keep up-to-date with the latest news.

About Oncology Consultants P.A.

Oncology Consultants P.A. is a community-based practice of physicians committed to providing state-of-the-art cancer treatment

Find out more at

Media Contacts


Weber Shandwick

Heather Platisha

+1 (206) 576-5558

Oncology Consultants

Souki Fournier

+1 (713) 800-0662